

SAFETY DATA SHEET

Section 1: Identification

Sildenafil citrate for Oral Suspension 10 mg/mL Material

Other means of identification None.

Recommended use Pharmaceutical product used for Treatment of pulmonary arterial

hyperten

Manufacturer Annora Pharma Private Limited, Survey No. 261, Annaram

Village, Gummadidala Mandal, Sangareddy, Telangana 502313,

India (IND)

Camber Pharmaceuticals, Inc., Piscataway, NJ 08854 **Distributor**

Section 2: Hazard(s) Identification

Hazard Classification: Not Classified as Hazardous

May be harmful if swallowed. May cause eye irritation (based on Additional Hazard Information:

components) Animal studies indicate that this material may cause

adverse effects on the cardiovascular system.

Adverse effects most commonly reported in clinical use include **Known Clinical Effects:**

difficult digestion (dyspepsia), nose bleed, headache, flushing, insomnia, abnormal redness of skin (erythema), difficulty breathing, muscle pain, fever, gastrointestinal irritation,

tingling/itching (paresthesia), transient changes in light perception

and color vision, effects on hearing, and effects on vision.

Section 3: Composition/Information on Ingredients

API Sildenafil citrate CAS 171599-83-0

Section 4: First-Aid Measures

Description of First Aid Measures

Never give anything by mouth to an unconscious person. Wash Ingestion

out mouth with water. Do not induce vomiting unless directed by

medical personnel. Seek medical attention immediately.

Remove contaminated clothing. Flush area with large amounts of **Skin Contact**

water. Use soap. Seek medical attention.

Flush with water while holding eyelids open for at least 15 **Eye Contact**

minutes. Seek medical attention immediately.

Inhalation Remove to fresh air and keep patient at rest. Seek medical

attention immediately.

Section 5: Fire-Fighting Measures

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products:

Fire Fighting Procedures:

Formation of toxic gases is possible during heating or fire. During all fire fighting activities, wear appropriate protective

equipment, including self-contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Section 6: Accidental Release Measures

Personal Precautions, Protective

Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental precautions Place waste in an appropriately labelled, sealed container for



disposal. Care should be taken to avoid environmental release.

Methods and Materials for Contamination and Cleaning Up

Measures for Cleaning /

Collecting:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids.

Clean spill area thoroughly.

Additional Consideration for

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

Section 7: Handling and Storage

Precautions for safe handling Minimize dust generation and accumulation. Avoid breathing

dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls. Refer to Section 12 - Ecological Information, for information on

potential effects on the environment.

Conditions for safe storage, including any incompatibilities

Store at room temperature, 20°C-25°C (68°F-77°F) [see USP

Controlled Room Temperature].

Section 8: Exposure Controls/Personal Protection

Control Parameters Refer to available public information for specific member

state Occupational Exposure Limits.

Engineering Controls

Engineering Controls

Engineering Controls

control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in

this section.

Personal protective EquipmentRefer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

If the applicable Occupational Exposure Limit (OEL) is exceeded.

Respiratory protection wear an appropriate respirator with a protection factor sufficient

to control exposures to below the OEL

Hands Impervious gloves are recommended if skin contact with drug

product is possible and for bulk processing operations. Wear safety glasses or goggles if eye contact is possible.

Skin Impervious protective clothing is recommended if skin contact

with drug product is possible and for bulk processing operations.

Section 9: Physical and Chemical Properties

Section 9, Physical and chemical properties

Physical Form Powder

Eyes

White to off white grape flavored powder.

Sildenofil for Oral Suspension		
Package Configuration	Strength	NDC



Powder for oral Suspension-10 mg/mL bottle (when reconstituted)

Section 10: Stability and Reactivity

Reactivity No data available

Chemical stability Stable under normal condition of use.

Possibility of hazardous

reactions

None

Oxidizing Properties No data available Conditions to avoid Not known

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

Hazardous decomposition

products

No data available.

Section 11: Toxicological Information

Information on Toxicological Effects

General Information The information included in this section describes the potential

hazards of the individual ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Sildenafil citrate

Mobility, Persistence and

Rat 300-500 mg/kg oral LDmin. 500-1000 mg/kg Mouse oral LDmin. LD50 >2000 mg/kg Rat Dermal

Section 12: Ecological Information

Environmental Overview: In the environment, the active ingredient in this formulation is

> expected to remain in water or migrate through the soil to groundwater. Harmful effects to aquatic organisms could occur. The active ingredient in this formulation is water soluble and is

Degradability: expected to remain primarily in water.

Bioaccumulation and Toxicity: The active ingredient in this formulation has low potential to

bioaccumulate and long-term adverse effects to aquatic organisms

are not expected. See aquatic toxicity data, below.

13. DISPOSAL CONSIDERATIONS

Disposal Procedures: Dispose of waste in accordance with all applicable laws and

regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive

techniques for waste and wastewater.

Section 14: Transport Information

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

Section 15: Regulatory Information

EU Indication of danger: Not classified



OSHA Label: Non-hazardous in accordance with international standards for workplace safety

Section 16: Other Information, including date of preparation or last revision

Issue Date: 27-05-2021

Version: 00

Further information Revision date: Nil Revision note: Nil

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.

Annora Pharma Private Limited shall not be held liable for any damage resulting from handling or from contact with the above product. Annora Pharma Private Limited reserves the right to revise this SDS.